Agilent: CFO Bob McMahon, 2/20/2019: “The tariffs were about roughly $4 million in the quarter which was in line with
what we had expected, so year-over-year that's a $4 million kind of headwind.”
Bruker: CEO Frank Laukien, 6/20/2019: “With respect to the tariff issue, we do not have an import volume of activity
coming into the U.S. from China, it's very de minimis generally, component elements of our business are pretty modest. It's
the outward side from the U.S. going back to China where we would be subject to retaliatory tariffs… If there is a further
slowdown in China clearly that would have some impact to us as well as everyone else in our space. But in terms of tariffs,
we're not seeing that as a major issue.”
Illumina: CFO Sam Samad, 5/15/2019: “Fast-forward to 2019, obviously, there's a lot of noise now in terms of tariffs being
placed on our end, on Chinese products and the potential retaliation from China. Again, we have no reason to believe that
there's any tariffs that are going to be placed on our consumables, or that the tariffs would be increased on our instruments.
So far, it's still 5% on our instruments from the 2018 tariffs that were placed and none on consumables.”
Hologic: CEO Steve MacMillan, 7/31/2018, “On the subject of international, and in response to recent news, let me
mention that while China represents only about 3.5% of our total sales, several of our products are included on the
expanded list of potential Chinese tariffs. So while we do not think these potential tariffs would have a significant impact on
the company, we are keeping a close eye on the situation.”
Mettler Toledo: CFO Shawn Vadala, 5/19/2019, “In terms of any potential third crunch at tariffs, more than 90% of our
imports from China are now subject to the 25% tariff. So much less exposure if there's any on a third potential tranche. In
China, we also don't sell a lot to exporters or other industries that are really feeling the direct impact of the tariff. So, so far,
we haven't really felt much of an impact on our Chinese business. But our bigger concern would be the general risk to the
Chinese economy, maybe some of the neighboring Asian economies or even the global economy.”
PerkinElmer: CEO Rob Friel, 11/29/2018: “For us, the risk is, of the $600 million that we sell into China, about $80 million
are products that are made in the U.S. and are shipped into China. And today, it varies between 0% and 10%. On average,
it's about a 5% tax. So that 5% we're either passing on or absorbing it some way, right? So, it really hasn't been an area.
Now, clearly, if everything goes to 25%, that's going to be something that we're going to have to deal with. And probably
what we would do, we've sort of mapped it out. We would probably move a couple products out of the U.S. It's not
something we would prefer to do, because obviously, whenever you move products, it's disruptive but it's something we
probably could do six to nine months, something like that.”
Thermo Fisher: CEO Marc Casper, 7/29/2019: “We assume that there is no change in the trade tariff environment in 2019
versus our previous guidance. And as a reminder, we expect that the year-over-year growth tariff impact to be $30 million,
which is just over 10 basis points of margin and approximately $0.07 of adjusted EPS.”